Astellas Pharma
Manufacturing · Japan · 14,510 Employees
View Company Info for Free
About
Headquarters
2-5-1 Nihonbashi-honcho Chuo-ku, Tokyo, Tokyo, ...Phone Number
+81 332443000Website
astellas.comRevenue
$11.2 BillionStock Symbol
ALPMFIndustry
Most Recent Scoops
Highlights
$212.5M
Total Funding Amount
$75M
Most Recent Funding Amount
4
Number of Funding Rounds
Who is Astellas Pharma
Astellas Pharma Org Chart
Is Astellas Pharma your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Astellas Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Astellas Pharma recently announced quarterly report
Check if Astellas Pharma has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Astellas Pharma has new funding data
Check out if Astellas Pharma is spiking on competitors!
Click to see if Astellas Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Astellas Pharma
Product Launch: Get notified when Astellas Pharma launches new products
Recommended Actions
Reach out to Masked Content who joined Astellas Pharma as Masked Content
Find 3 more new buyers
Compare Similar Companies to Astellas Pharma
Compare insights from companies similar to Astellas Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Astellas Pharma Email Formats
Astellas Pharma uses at least 5 email formats with first.last (ex. John.Smith@astellas.com) being used 83.4% of the time
Astellas Pharma Email Formats | Percentage | |
---|---|---|
first.last | John.Smith@astellas.com | 83.4% |
first + last | JohnSmith@astellas.com | |
first_last | John_Smith@astellas.com | |
first | John@astellas.com | |
last | Smith@astellas.com |
Get Verified Emails
Astellas Pharma financials insights
Gather financial insights about Astellas Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Astellas Pharma Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Astellas Pharma Tech Stack
A closer look at the technologies used by Astellas Pharma
Most Recent Scoops
Astellas Pharma News & Media
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Vyloy® (zolbetuximab-clzb)
LOUISVILLE, Ky., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Astellas for Vyloy® (zolbetuximab-clzb), approved in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction adenocarcinoma whosAstellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
SAN FRANCISCO, Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DOHC), a member of Heritage Provider Network, to pilot DIGITIVA™, a non-invasive digital...Astellas Pharma Inc. (ALPMF) Q2 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2024 Earnings Call Transcript October 30, 2024 2:30 AM ETCompany ParticipantsHiromitsu Ikeda - Chief Communications...Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura,...
Frequently Asked Questions Regarding Astellas Pharma
Astellas Pharma is engaged in the manufacturing, marketing, import, and export of pharmaceuticals. It is headquartered in Tokyo, Japan.... Read More